News Related to Doxorubicin

Related coverage linked through entity extraction aliases.

MSD says sac-TMT met primary endpoints in Phase III endometrial cancer trial

May 19, 2026

MSD said sacituzumab tirumotecan improved overall survival and progression-free survival in the Phase III TroFuse-005 trial in endometrial cancer. The study also met its objective response rate endpoint.

Morning Dosing of Cancer Immunotherapy Extends Survival in Lung Cancer Trial

Feb 13, 2026

A randomized trial of 210 advanced lung cancer patients found that administering checkpoint inhibitor immunotherapy in the morning nearly doubled progression-free survival and extended overall survival by nearly a year compared to later-day dosing.